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Abstract
Background: Homeobox B9 (HOXB9), a transcriptional factor, regulates developmental processes and tumor
progression and has recently been recognized as one of important transcriptional factors related to angiogenesis.
This study aimed to investigate the role of HOXB9 in tumorigenesis and angiogenesis.
Methods: We examined the expression of HOXB9 in colorectal cancer using qPCR and in situ hybridization. We also
examined the effect of HOXB9 overexpression in colorectal cancer using a proliferation assay, ELISA, a multiplex
assay, and xenograft models. The clinical significance of HOXB9 was statistically evaluated in resected specimens.
Results: HOXB9 was expressed in colorectal cancer specimens. HOXB9 induced angiogenesis and tumor
proliferation in vitro, which resulted in high tumorigenicity in vivo and poor overall survival. Bevacizumab, an
anti-vascular endothelial growth factor (VEGF) antibody, remarkably suppressed tumor proliferation by inhibiting
angiogenesis in HOXB9-overexpressing xenografts, and it improved overall survival and provided prolonged
progression-free survival in HOXB9-overexpressing patients. A comprehensive multiplex assay of the supernatant
of cancer cells co-cultured with human vascular endothelial cells and fibroblasts indicated significantly higher
interleukin-6 (IL6) levels than those in the supernatant of monocultured cells. HOXB9 overexpression in clinical
specimens was significantly correlated with increased IL6 expression. An IL6-neutralizing antibody inhibited VEGF
secretion and tumor proliferation in the co-culture system.
Conclusions: HOXB9 promotes the secretion of angiogenic factors, including VEGF, to induce tumor proliferation
through microenvironmental production of cytokines including IL6 signaling. Moreover, silencing of VEGF or IL6
terminates cytokine release in tumor microenvironment. Thus, HOXB9 and IL6 may be potential biomarkers for
bevacizumab treatment.
Keywords: Colorectal cancer, Aangiogenesis, Bevacizumab, Biomarker
Background
Homeobox (HOX) genes are key regulators of embryonic
development and are evolutionarily conserved [1]. Thirty-
nine HOX genes are arranged in 4 different clusters, that
is, HOXA–HOXD. Homeobox B9 (HOXB9) is expressed
in several adult human tissues, including the endomet-
rium [2], mammary glands [3], and blood precursor cells
[4]. HOXB9 has been shown to be overexpressed in hu-
man breast cancer and is associated with tumorigenicity,
lung metastasis, and radioresistance [5,6]. Especially,
HOXB9 induced tumor proliferation and metastasis by
activating angiogenesis [5], but little is known about the
relationship between HOXB9 expression and angiogenesis
in colorectal cancer, which is widely treated by anti-
angiogenic therapy in combination with chemotherapy,
and about the impact of anti-angiogenic treatment on
tumors with angiogenic properties.
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[7,8] and cancer metastasis [9] because the generation
of new vessels to meet the metabolic demands of
under-perfused regions promotes tumor growth. Vas-
cular network recruitment provides the principal
route by which tumor cells exit the primary tumor
site and enter the circulation. Thus, angiogenesis has
become a target for cancer therapy through inhibition
of vascular endothelial growth factor (VEGF) signaling
by various drugs, including bevacizumab, sorafenib,
and sunitinib.
Bevacizumab is a humanized monoclonal antibody
that inhibits VEGF activity. Because VEGF stimulates the
angiogenesis of microvessels, bevacizumab is proposed
to function by blocking neovascularization in the tumor
microenvironment [10,11] and by reducing vascular per-
meability in tumor microvessels [12,13]. Bevacizumab
has become one of the standard components of chemo-
therapy for metastatic or recurrent colorectal cancer, but
no biomarkers are available to determine the efficacy of
anti-VEGF therapy.
It is important to investigate the mechanisms under-
lying anti-angiogenic treatment, especially in highly vas-
cular tumors. Here, the clinical significance of HOXB9
expression was assessed, and the angiogenic and onco-
genic functions of HOXB9 were further examined
in vivo and in vitro. In the present study, we have dem-
onstrated that anti-angiogenic treatment inhibits tumor
proliferation driven by HOXB9 overexpression and de-
creases the tumor burden by silencing cytokine crosstalk
in microenvironment.
Results
HOXB9 expression in colorectal cancer patients
To investigate HOXB9 expression in colorectal cancer,
we examined specimens from patients who had p-stage II
or III colorectal cancer and had undergone surgery at
our institute. HOXB9 mRNA was expressed in ap-
proximately 70% of the patients (Figure 1a), and
HOXB9 was found to be upregulated in a fraction of
tumors, relative to that in the uninvolved adjacent
normal mucosa, in both RNA in situ hybridization
(Additional file 1: Figure S1a), and immunohisto-
chemical staining (Figure 1b). HOXB9 mRNA expres-
sion was significantly higher in poorly differentiated
adenocarcinomas than in highly and moderately dif-
ferentiated types of adenocarcinomas (Figure 1c) and
was highly related to liver metastasis (Additional file 1:
Figure S1b). Moreover, although HOXB9 did not
affect the disease free survival after surgery, increased
HOXB9 expression in colorectal cancer was signifi-
cantly associated with a poor prognosis in overall sur-
vival (Figure 1d), as previously reported for breast
cancer [14].
Role of HOXB9 in angiogenesis, TGF-beta axis and
tumorigenesis
We introduced the HOXB9 construct into the HT29
and HCT116 cancer cell lines (HT29-T and HCT116-T,
respectively), both of which showed low HOXB9 mRNA
expression relative to that in the other human colorectal
cancer cell lines (Additional file 1: Figure S1c), in order
to evaluate the functional consequence of HOXB9 over-
expression in colorectal cancer. HOXB9 overexpression
is regulated by a tetracycline repressor (Figure 1e,f and
Additional file 1: Figure S1d,e) [15]. Angiogenic factors,
including amphiregulin (AREG), epiregulin (ERG), basic
fibroblast growth factor (bFGF), interleukin-8 (IL8),
and VEGF were significantly upregulated by HOXB9
(Figure 1g). To determine the effect of the loss of
HOXB9, we produced short hairpin RNA (shRNA)-
expressing HOXB9 lentiviral constructs capable of re-
ducing endogenous HOXB9 expression by up to 99%
(Figure 1e). These constructs were used to reduce the
expression of angiogenic factors in WiDr and SW480 cell
lines (WiDr-S and SW480-S, respectively) that initially
had high expression of HOXB9 (Figure 1g). Moreover, the
transforming growth factor (TGF) -beta axis was regulated
by HOXB9 in colorectal cancer (Figure 1h), similar to the
results previously obtained for breast cancer [5]. Next, we
investigated the functional significance of these factors
in ELISA assays. Significantly increased tumoral secre-
tion of angiogenic factors were confirmed in the superna-
tants of HOXB9-overexpressing cell lines (Additional file 2:
Figure S2a,b). To confirm the role of this acquired
angiogenesis of colorectal cancer in vivo, we estab-
lished human tumor xenografts in BALB/c nude mice.
HOXB9-overexpressing xenografts of the HT29-T cell
l i n ed e m o n s t r a t e dad r a m a t i ci n c r e a s ei nt u m o rb u r d e n
(Figure 2a,b) and microvessel density (Figure 2c,d and
Additional file 2: Figure S2c). The immunohistochemical
staining showed higher production of angiogenic factors
including IL8 and VEGF in HOXB9 overexpressed tumor
(Additional file 2: Figure S2d).
Inhibition of angiogenesis in HOXB9-overexpressing
tumors
The cell proliferation test for 24 hours revealed almost
the same proliferation in HOXB9 overexpressed cells as
control (Additional file 3: Figure S3a), and the cell viabil-
ity test for 7 days showed rather smaller survival rate in
HOXB9 overexpressed cells in vitro (Additional file 3:
Figure S3b). Therefore, the role of the microenviron-
ment in tumor proliferation under the regulation of
HOXB9 was investigated, given that the primary differ-
ence between the in vivo and in vitro conditions was the
existence of a microenvironment including vessels and
fibroblasts. When HUVECs and human dermal fibro-
blasts (HDFs) were co-cultured with cancer cell lines to
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http://www.molecular-cancer.com/content/13/1/102mimic the microenvironment (Additional file 3: Figure
S3c,d), HOXB9 significantly promoted cell proliferation
(Figure 3a). Then, we hypothesized that anti-angiogenic
treatment may cause strong regression in tumors with
such angiogenic properties as HOXB9, which depends
tumor proliferation on enhanced angiogenesis and stromal
reaction in the microenvironment. In order to evaluate the
impact of anti-angiogenic agents on tumor microenviron-
ment in vitro, the tube formation of HUVECs co-cultured
with HOXB9-regulated cancer cells was estimated under
administration of bevacizumab. HOXB9 significantly
enhanced angiogenesis, and bevacizumab administration
significantly reduced angiogenesis of HUVECs co-cultured
with HOXB9-overexpressing cancer cells (Figure 3b and
Additional file 3: Figure S3e,f).
Next, BALB/c nude mice transplanted with xenografts
that had been previously established using HOXB9-
overexpressing colon cancer cells were treated intrape-
ritoneally with bevacizumab (5 mg/kg, weekly). Both of
HOXB9-induced cancer cells showed accelerated tumori-
genesis. However, the bevacizumab treatment dramatically
reduced tumor volume and tumor weight both in HT29-T
cells (Figure 4a,b) and in HCT116-T (Additional file 4:
Figure S4a,b). Tumor gross vascularity was also reduced
by bevecizumab (Figure 4c). The growth inhibition medi-
ated by bevacizumab significantly increased in HOXB9-
overexpressing tumors (Figure 4d,e and Additional file 4:
Figure S4c,d). We further established an intrasplenic
injection (ISP) model of HCT116-T cells in BALB/c nude
mice to determine whether anti-angiogenic treatment with
bevacizumab prolongs survival in angiogenic tumors.
HOXB9 overexpression was associated with longer
third-quadrant survival upon bevacizumab treatment
(Additional file 5: Figure S5a,b). To vertify our hypo-
thesis that the loss of angiogenic factors plays an important
role in tumor shrinkage in angiogenesis-driven tumor, su-
nitinib malate, which is a multiple tyrosine kinase inhibitor
with effects including VEGF inhibition, was also adminis-
tered in HOXB9 overexpressed tumor. Sunitinib also sup-
pressed cell proliferation in HOXB9-overexpressing breast
cancer xenografts (Additional file 5: Figure S5c).
Enhanced cytokine release from microenvironment
To determine the key factors for enhanced tumor growth in
microenvironment, we performed comprehensive multiplex
assays involving the co-culture supernatants and observed
significant elevation of the levels of several cytokines, in-
cluding interleukin-6 (IL6) (Figure 5a). We then focused
on the differences between the secretion of IL6 in mono-
culture and co-culture systems to elucidate the impact of
microenvironment on tumor proliferation. The concentra-
tion of IL6 was dramatically higher in the co-culture sys-
tem than in the mono-cultures (Figure 5b and Additional
file 6: Figure S6a), suggesting enhanced IL6 secretion in
microenvironment including tumor and stromal cells. To
confirm the importance of microenvironmental IL6 secre-
tion, cell proliferation in the presence of an IL6 neutraliz-
ing antibody was evaluated. We also used bevacizumab to
inhibit the activity of VEGF released from cancer cells
(Figure 5c). Both the IL6 neutralizing antibody and bevaci-
zumab produced significant reduction of cancer cell pro-
liferation (Figure 5d,e and Additional file 6: Figure S6b).
Moreover, IL6 secretion in the supernatant dramatically
decreased on administration of bevacizumab in co-culture
systems (Figure 5f).
Clinical significance of HOXB9 on bevacizumab treatment
To clarify the clinical significance of anti-angiogenic
treatment for angiogenic colorectal cancer, we conducted
a retrospective study of patients who had undergone
surgery between 2001 and 2010 at our institute and were
treated by chemotherapy, including bevacizumab (n=39).
Specimens obtained from patients before chemotherapy
were analyzed by Quantitative reverse transcription-PCR
(qRT-PCR). The demographic and clinical data showed no
significant differences with regard to age, sex, pathological
stage, or chemotherapy between groups with high (n=13)
or low (n=26) expression of HOXB9 (Additional file 7:
Table S1). High expression of HOXB9 mRNA was sig-
nificantly associated with longer overall survival and
progression-free survival after treatment with bevaci-
zumab combined with chemotherapy (Figure 6a,b),
and mRNA expression of HOXB9 was significantly corre-
lated with IL6 mRNA expression in clinical specimen
(Figure 6c).
Discussion
HOXB9 has been reported to be overexpressed in
neoplastic tissues [16]; to promote the expression of
angiogenic factors, ErbB, and TGF-beta ligands; and
(See figure on previous page.)
Figure 1 HOXB9 expression in colorectal cancer. (a) Waterfall plot of relative mRNA expression levels of HOXB9 in patients at the cancer site
compared with those in normal mucosa (n=69), determined using qRT-PCR in triplicate. (b) Immunohistochemical staining of HOXB9 in resected
colorectal cancer specimens (T, tumor; N, normal mucosa). (c) Relative mRNA expression of HOXB9 in patients according to pathological differentiation
(Well/ mod, well or moderately differentiated adenocarcinoma; Por, poorly differentiated adenocarcinoma). (d) Kaplan-Meier curves of colorectal cancer
patients (n=93), according to HOXB mRNA expression (Left panel, disease free survival; right panel, overall survival). (e) mRNA expression of HOXB9
determined by RT-PCR. (f) Immunocytochemistry of HOXB9-overexpressing cell lines. (g and h) mRNA expression of angiogenic factors (g) and TGF
beta family (h) in HOXB9-overexpressing cell lines using RT-qPCR in triplicate. Error bars are SDs. P values by the log rank test. Scale bars, 100 μm.
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http://www.molecular-cancer.com/content/13/1/102Figure 2 Impact of HOXB9 expression on tumor xenografts. (a, b) Subcutaneous xenograft model of HT 29-T cells was established in Balb/c
nu/nu mice (n =8, each). Tumor burden (a) and tumor weight (b) were evaluated. (c) Immunohistochemical staining of paraffin-embedded
xenografts obtained from HT29-T cancer cells. Samples were stained in anti-HOXB9 or anti-CD31. (d) Microvessel density of xenograft tumor was
evaluated and measured in immunohistochemical staining by ant-CD31 antibody in xenografts (n= 8, each). Error bars are SDs. ⋆ p< 0.05 and
† p<0.005 by U-test. Scale bars, 200 μm.
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breast cancer [5]. From a biological perspective, multiple
HOX-binding sites have already been identified in the pro-
moters of angiopoietin-like 2, IL8, TGF-beta2, VEGF, and
bFGF [17]. AREG, ERG, VEGF, and bFGF were previously
revealed to be the direct targets of HOXB9 [5,18]. In bio-
informatic analysis using PROMO3.0 (http://alggen.lsi.
upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=
TF_8.3), we found multiple sequences in the promoter
regions of IL8 where HOX genes were predicted to bind.
In the present study, we demonstrated that HOXB9 also
promoted the expression of angiogenic factors and TGF-
beta ligands in colorectal cancer. Tumorigenesis was
enhanced by the microenvironment, as demonstrated by
stromal interaction and neovascularization in HOXB9-
overexpressing tumors in vivo. In addition to angiogenesis,
the stromal response has been suggested as one of the
determinants of tumor proliferation and recurrence in
colorectal cancer [19]. The tumor stroma is activated by
TGF-beta signaling, which leads to upregulation of extra-
cellular matrix proteins and inflammatory, angiogenic,
and invasion factors that promote the growth of tumor
cells [20,21]. A study involving chromatin immunoprecipi-
tation previously demonstrated that HOXB9 binds to the
TGF-beta2 promoter region as a transcriptional factor to
regulate gene expression [5]. Taken together, the activation
of angiogenesis and TGF-beta axis in vitro may result in
strong tumorigenesis in vivo and poor overall survival in
colorectal cancer patients.
To vertify our hypothesis that angiogenic tumors
which depend the tumorigenity on angiogenesis are
more sensitive to anti-angiogenic treatment, the present
study has demonstrated three important findings: the
relationship of HOXB9 to colorectal cancer tumorigen-
icity in vitro and in vivo in terms of angiogenesis and
TGF beta signaling; the association of VEGF and anti-
angiogenic agents with the tumorigenic HOXB9 effect;
and, the association of HOXB9 with accelerated cytokine
release from tumor microenvironment. For the investiga-
tion of tumor suppression by bevacizumab administration,
we performed the multiplex assay for comprehensive
detection of enhanced cytokine production induced by
HOXB9 in co-culture experiments. Our study which com-
pared co-culture with mono-culture demonstrated that
tumorigenic effects of HOXB9 in the microenvironment
resulted in the enhanced release of various cytokines and
that IL6 release from tumor microenvironment plays an
important role in tumor proliferation. Not only silencing
of IL6 led to the reduction in the proliferation of tumor in
co-culture experiments, but also bevacizumab adminis-
tration reduced IL6 release itself from tumor microen-
vironment. Thus, these on-and-off results for HOXB9
expression and neutralizing antibodies suggest our hy-
pothesis that bevacizumab inhibits HOXB9 induced
tumor proliferation by silencing microenvironmental cyto-
kine release including VEGF and IL6 (Additional file 6:
Figure S6c). The microenvironment in humans includes
not only vessels and fibroblasts but also immune systems,
which results in complicated interactions. In the present
study, the predominance of cytokine secretion between
tumor and stroma is not evident, and a role for IL6 as
another mediator cannot be excluded. But our data sug-
gest a possible role for microenvironmental IL6 in tumor
cell proliferation, at least with regard to angiogenesis.
Our results are consistent with those of previous stud-
ies demonstrating that IL6 affects microenvironment.
IL6 levels are known to be increased in most epithelial
tumors [22], and high serum IL6 levels are associated
with poor clinical outcomes in patients with colorectal
cancer [23] or ovarian cancer [24]. IL6 is a key mediator
in a mouse model of microbially induced colorectal cancer
[25], possibly through induction of cancer-related molecu-
lar pathways such as those involving STAT3 [26].
Several limitations affect the interpretation of the
present findings. First, this translational study was based
Figure 3 Impact of cytokine release from HOXB9 overexpressed
cells on angiogenesis and cell proliferation. (a) Cancer cells
(3000 cells/well) were seeded on micropore membrane over 24-wells
plate and incubated for 24 h before tetracycline administration and/or
co-culture with HUVECs and HDFs. After 48 hours incubation with
tetracycline and/or co-culture system, the number of cancer cells were
counted (n=8, each). (b) Total capillary length of co-cultured HUVECs
were evaluated in immunohistochemical staining of CD31 after
48 hours incubation with HOXB9 induced cell lines (n=8, each). Error
bars are SDs. ⋆p<0.05 by the U-test.
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number of patients were included. Second, the selection
of patients for the bevacizumab treatment was subject-
ive. The clinical significance of HOXB9 and IL6 must
therefore be addressed in a prospectively planned multi-
center trial. Multigene assays involving a large number
of specimens may provide more reliable insights into
tumor biology and the response to bevacizumab regi-
mens. Third, the relationship between the immuno-
logical response and chemotherapy combined with anti-
angiogenic treatment is unclear because bevacizumab
was not administered as a single agent in our clinical
study. Fourth, the impact of a combined cytotoxic che-
motherapy regimen is unclear; the results obtained in
the present study are biased by the chemotherapy itself.
Conclusions
HOXB9 is also expressed in colorectal cancer and func-
tions as a strong tumorigenic factor through activation
of the TGF-beta axis and angiogenesis. Colorectal cancer
patients with HOXB9 overexpression had poor overall
survival in this study, but conversely demonstrated better
overall survival with bevacizumab treatment. Bevacizumab
suppressed secretion of IL6 into the microenvironment
Figure 4 Bevacizumab treatment and HOXB9 expression. Subcutaneous xenografts of HT 29-T cells in Balb/c nu/nu mice were treated with
bevacizumab (n= 8, each). Tumor growth under bevacizumab treatment were evaluated in tumor burden (a), tumor weight (b), tumor specimen
(c), and tumor inhibition rate (d). (e) Tumor inhibition rate was calculated in HT 29-T on day 13. Error bars are SDs. ⋆p<0.05 and † p<0.005
by U-test.
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http://www.molecular-cancer.com/content/13/1/102Figure 5 HOXB9 expression and co-culture systems. (a) Cancer cells were co-cultured with HUVECs and human fibroblasts for 48 hours.
Cytokines in supernatants were evaluated by multiplex assays (n=24, each). (b) IL6 secretion levels in supernatants were compared by ELISA between
the monoculture and co-culture systems in HT29-T or HCT116-T cancer cells. HOXB9 overexpression was induced by tetracycline (1 μg/ml). (c) VEGF
secretion and bevacizumab treatment in the co-culture system, detected by ELISA (HT 29-T, left panel; WiDr-S right panel). (d, e) Tumor proliferation of
HT29-T (d) and HCT116-T (e) cell lines on treatment with bevacizumab and/or an IL6-neutralizing antibody in the co-culture system with HUVECs and
human fibroblasts. (f) IL6 secretion under treatment with bevacizumab and/or IL6 neutralizing antibody in the co-culture system with HUVECs and
human fibroblasts. Error bars are SDs. ⋆ p<0.05 and † p<0.005 by the U-test.
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increased response to bevacizumab treatment. Previous
studies have reported the clinical impact of some genes,
including VEGF splice isoforms or neuropilin-1 (NRP-1)
[27]. However, to date, no biomarkers have been identified
in randomized controlled trials on the clinical response of
anti-angiogenic treatments in colorectal cancer [28]. Fur-
ther prospective studies on HOXB9 and IL6 in different
specimens such as serum samples are important to clarify
the utility of these molecules as biomarkers.
Figure 6 Clinical data for colorectal cancer patients undergoing bevacizumab treatment. HOXB9 mRNA expression levels were evaluated
in triplicate by qRT-PCR in patients who showed recurrence after surgery and were treated by chemotherapy combined with bevacizumab
(a and b) Kaplan-Meier curves of colorectal cancer patients, according to HOXB mRNA expression. Progression-free survival (a) and overall survival (b).
p values by the log rank test. (c) IL6 mRNA expression in colorectal cancer specimens. Error bars are SDs. P values by the U-test and log rank test.
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mRNA expression
Our analysis included colorectal tumors of patients who
presented between January 2004 and January 2008 at
Keio University Hospital; these data were obtained from
the hospital colorectal cancer database. Among the sam-
ples of consecutive sporadic colorectal cancer patients
who received a diagnosis of p-stages II or III disease, 69
panels of frozen tissue specimens containing cancerous
and matched normal mucosal tissue were available for
qRT-PCR assessment. All samples were obtained from
surgically resected material, immediately frozen in liquid
nitrogen, and stored at −80°C. Adequate lymph node
dissection was performed in all these cases, and a patho-
logical diagnosis was made according to the TNM classi-
fication. HOXB9 mRNA expression was examined at
cancer sites and in normal mucosa in consecutive
pStages II and III patients who had undergone surgery
at our institute during 2004–2008. The expression ratios
(cancer site to normal mucosa) were examined using
qRT-PCR. RNA was extracted from the cells by using
the RNeasy kit (QIAGEN, Valencia, CA). Conditions for
semiquantitative amplification of cDNA were 95°C for
2 min, followed by 25 cycles of 95°C for 30 s, 56°C for
30 s, and 72°C for 60 s, with a final extension cycle of
72°C for 10 min. RT-PCR analysis was run in triplicate
for each sample on a Light Cycler 480 Real-Time PCR
System using SYBR Green 1 Master Mix (Roche). The
following program was run: preincubation for 5 min at
95°C, amplification for 45 cycles (10 s of denaturation
at 95°C, 10 s of annealing at 57°C, and a 10-s extension
at 72°C), and melt-curve analysis. mRNA levels of the
target gene were normalized against mRNA levels of
GAPDH, which was used as an internal control. The
sequences of all the primers used are listed in Additional
file 8: Table S2. Written informed consent was taken and
the study was approved by the ethics committee of the
School of Medicine of Keio University.
In situ hybridization
The HOXB9 probe for ISH was generated as described
previously [5]. Briefly, the plasmid encoding HOXB9
was cleaved with Hinc II and XmaI (New England
Biolabs). The acquired 286-bp fragment was outside
the homeodomain and spanned nucleotides 26–324 of
the HOXB9 transcript. This region had 100% homology
to HOXB9, as expected, and had little homology with
other members of the HOX family or other HOX genes.
After linearization of the plasmid, in vitro transcription
was carried out, using 11-digoxogem-UTP (Roche) and 2
units/μL of either T3 of T7 RNA polymerase (Promega)
for sense and antisense probes, respectively. Riboprobes
were purified by ethanol precipitation, and their size and
integrity checked by gel electrophoresis. The tissues were
dehydrated, washed twice with PBS, and treated with 3%
hydrogen peroxide for 15 min. Following treatment with
proteinase K (10 μg/ml) for 9 min, tissues were washed
with PBS and refixed with 4% paraformaldehyde in PBS
for 5 min. The tissues were pre-hybridized for 1 hr at
65°C before hybridizing with sense or anti-sense dig-
oxigenin-labeled riboprobes overnight at 70°C. After
hybridization, samples were placed in 1% sheep serum
for 30 min at room temperature, and then incubated
with anti-digoxygenin-AP (Roche) antibody for 2 hours
at room temperature. BM-Purple precipitation (Roche)
was used to detect the signal.
Cell lines and cell culture
The human colorectal cancer cell lines SW480, WiDr,
HT-29, and HCT116 were obtained from the American
Type Culture Collection (Rockville, MD). The cell lines
HT29 and HCT116 were seeded at a density of 1×10
6/ml
in RPMI 1640 medium (Gibco, MA), and SW480 and
WiDr cells were seeded a density of 1×10
6/ml in
Dulbecco’s modified Eagle medium. Both media were
supplemented with 10% FBS (CSL Ltd., Australia),
100 IU/ml penicillin, and 50 mg/ml streptomycin sulfate.
HT29 and HCT116 cells with low HOXB9 expression
were infected with HOXB9-expressing lentiviral con-
structs (Invitrogen). For the Tet-regulated system, the
entry vector was transferred to the lentiviral pLenti4/TO/
V5-DEST vector and used in combination with the Tet-
repressor vector pLenti6/TR (Invitrogen) according to the
manufacturer’s instructions. The induction of HOXB9 was
regulated by the addition of 1 μg/ml tetracycline (Invitro-
gen). To knock down HOXB9 expression, viral constructs
of shRNA were generated, and SW480 and WiDr cells
were infected as described previously [5].
Edu cell proliferation assay
DNA synthesis was measured using 5-ethynyl-2´-deoxyuri-
dine (EdU) Flow Cytometry Assay Kits (Life Technologies,
Tokyo, Japan). Experiments were performed according to
the manufacturer’s instructions. Briefly, 3× 10
6 cells were
seeded into 10 cm dish and incubated for 24 hours at 37°C
with or without 1 μg/ml tetracycline (Invitrogen). Cells
were incubated for 2 hours with 20 μM EdU. Subsequently,
cells were processed using the Click-iT EdU Flow Cyto-
metry kit. EdU incorporation was measured by Flow
cytometer (Gallios Flow Cytometer, Beckman Coulter).
MTT cell proliferation assay
Cell proliferation was measured using the 2,3-bis (2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-car-
boxanilide inner salt (MTT) assay. Briefly, 5,000 cells
per well in 96-well microtiter plates (Sumilon, Sumitomo
Bakelite Co., Tokyo, Japan) were incubated for 24 h,
followed by continuous exposure to 1 μg/ml tetracycline
Hoshino et al. Molecular Cancer 2014, 13:102 Page 10 of 14
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measured at every 2 days using a NJ-2300 microplate
spectrophotometer at 540 and 630 nm (Immuno Reader,
Nalge Nunc International, Rochester, NY).
Western Blotting, Immunocytochemistry, and
immunohistochemistry
Expression of proteins were detected in western blotting
using antibody against HOXB9 (Santa Cruz Biote-
chonlogies), pAKT (Cell Signaling Technology), AKT
(Cell Signaling Technology), VEGF (ABCAM) and GAPDH
(ABCAM). The western blot protocols used have been
described previously [29]. For immunocytochemistry, cells
were plated in 8-well chamber slides (Lab Tek) and treated
as described previously [5]. Briefly, after blocking, the cells
were incubated with an anti-human HOXB9-specific anti-
body (rabbit polyclonal antibody; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) at a dilution of 1:250 or an anti-CD31
antibody (ab28364; ABCAM) at 1:200 for 1 h at room
temperature in incubation buffer (phosphate-buffered saline
(PBS) containing 1% BSA). For immunohistochemistry,
HOXB9, CD31, CD34, IL8, and VEGF expression was
detected using the anti-human HOXB9-specific antibody at
a dilution of 1:250 (Santa Cruz, CA), the anti-CD31 anti-
body at a dilution of 1:200 (ab28364; ABCAM), the anti-
CD34 antibody at a dilution of 1:200 (ab8158; ABCAM),
anti-IL8 antibody at a dilution of 1:1000 (ab7747; ABCAM),
the anti-VEGF antibody at a dilution of 1:1000 (ab46154;
ABCAM).
Angiogenesis in vitro and co-culture systems
Angiogenesis was evaluated based on the microvessel
density of HUVEC cultures. Culture supernatants with-
out FBS or antibiotic supplementation were assessed
using an angiogenesis kit (Kurabo, Okayama, Japan). Ex-
periments were performed according to the manufac-
turer’s instructions. The angiogenesis kit consisted of a
24-well cluster dish in which HUVECs and fibroblasts
were seeded under optimal conditions for capillary tube
formation. The microvessel density was calculated as the
sum of the total capillary length in 6 areas at 200× mag-
nification by using the ImageJ software (NIH, Bethesda,
MD). HUVECs and fibroblasts were co-cultured with
HOXB9-overexpressing cancer cells and separated from
the cancer cells by using micropore membranes. Each
well was cultured with serum-free medium correspond-
ing to each cell line, respectively.
Tetracycline was administered to regulate HOXB9
induction after 24 hours of co-culture. Endogenous IL6
was neutralized by application of an anti-IL6 antibody,
and VEGF neutralization was assayed in a co-culture
system in which 5 × 10
3 HOXB9-overexpressing cancer
cells were seeded per well in a medium supplemented
with 1 μg/ml anti-human IL6 antibody (R&D Systems)
and/or 1 μg/ml bevacizumab. HOXB9 expression was
controlled by the addition of tetracycline.
Multiplex assay
Cytokine levels in cell culture supernatants were quanti-
fied using ELISA (BD Biosciences Pharmingen for VEGF,
HGF, CXCR8, and IL6). Comprehensive proliferative cyto-
kine levels in co- and monoculture supernatants were mea-
sured using a Procarta Cytokine Profiling kit (Affymetrix,
Santa Clara, CA, USA), which utilizes xMAP multianalyte
profiling Luminex technology for simultaneous detection
and quantification of multiple protein targets. Fluores-
cently encoded antibody beads were detected individually
in a flow cytometer, and 9 cytokines (bFGF, G-CSF, GM-
CSF, HGF, IL1beta, IL6, MCSF, TGFbeta, and TGFalpha)
were evaluated.
Xenograft experiments
All the animals were cared for and experiments were
performed according to AAALAS guidelines using pro-
tocols approved by the institutional review board and
the institutional animal care and use committee of Keio
University or Massachusetts General Hospital. Six-week-
old Balb/c female nude mice were subcutaneously
implanted with 4×10
6 cells in 100 μl of PBS (n=8). If the
tumor size was greater than 75 mm
3, oral tetracycline
administration was started on day 1. Tetracycline (Sigma-
Aldrich) was dissolved in distilled water at a concentration
of 1 mg/ml. Bevacizumab (5 mg/kg) or PBS was intrape-
ritoneally administered weekly. The tumor volume was
calculated from the pi-based ellipsoid volume formula
π/6 × length × width × height. Growth inhibition of the
tumor was calculated as (1 – (mean tumor volume of
treated group/mean tumor volume of vehicle group))×
100. An intrasplenic injection (ISP) model was established
to create liver metastasis as described previously [30,31].
Briefly, nude mice were anesthetized by ether inhal-
ation, and open laparotomy was performed. HOXB9-
overexpressing cancer cells (5×10
6 cells of HCT116-T
in 100 μl of PBS) were injected into the spleen, and
splenectomy was then performed. Tumor samples were
immunostained using an anti-CD31 antibody (Abcam,
Cambridge, UK) and then counterstained with DAPI.
Vessels were counted using a microscope in areas of the
tumor containing the highest number of capillaries and
small venules. Highly vascular areas were first identified
by scanning tumor sections, and the vessels were counted
in 6 such areas at 200× magnification. Bevacizumab was
purchased from Chugai Pharmaceutical Co. Ltd (Tokyo,
Japan). MCF10A cells expressing activated G12V H-
RasV12-expressing lentivirus and either LacZ or HOXB9
were generated using standard protocols. Xenografts were
established by injecting 5×10
6 cells in 100 μlo fP B Si n t o
Hoshino et al. Molecular Cancer 2014, 13:102 Page 11 of 14
http://www.molecular-cancer.com/content/13/1/102the mammary fat pad of 6-week-old female Swiss nu/nu
mice. Tumor volumes were measured at regular intervals.
Sunitinib (SU11248; Sutent) was purchased from LC
Laboratories. MCF10A cells expressing activated G12V
H-Ras-expressing lentivirus and either LacZ or HOXB9
were injected into the mammary fat pads of mice (n=16).
After 2 weeks of tumor growth, 8 animals from each
group were treated with 40 mg/kg sunitinib orally every
day for up to 14 days. Sunitinib was dissolved in 0.5%
carboxymethyl cellulose. The remaining 8 animals from
each group were treated with the vehicle.
Patients and samples
Our analysis included 456 colorectal tumors of patients
who presented between January 2006 and January 2008
at Keio University Hospital; these data were obtained
from the hospital colorectal cancer database. Patients
who showed recurrence after surgery and were treated
by chemotherapy combined with bevacizumab were se-
lected from the database. Among the specimens from 77
consecutive patients, 39 specimens were available and
were analyzed by qRT-PCR. The study was approved by
the ethics committee of the School of Medicine of Keio
University.
Statistical analysis
Statistical analysis was performed using the SPSS 18.0
statistical software (SPSS, Chicago, IL). Analyses of age,
pathologic tumor size and weight, mRNA expressions,
and total capillary length were performed using the
Mann–Whitney U test. The tumor size, weight, and
burden were statistically evaluated at the time of sacri-
fice in xenograft models. Disease-free survival (DFS) and
overall survival (OS) curves were drawn according to
Kaplan–Meier estimates and compared by log-rank tests.
DFS was defined as the absence of local or regional
recurrence, distant metastasis, second primary carcinoma,
or death from any cause. The clinicopathologic categorical
variables were compared using Fisher’s exact test or logis-
tic regression where appropriate. The cutoff value for
HOXB9 mRNA expression was determined according to
the receiver operating characteristic curve. P<0.05 was
defined as significant.
Additional files
Additional file 1: Figure S1. HOXB9 expression in colorectal cancer is
associated with poor prognosis and enhanced angiogenesis. Relative mRNA
expression levels HOXB9 in patients at the cancer site compared with those
in normal mucosa, determined using qRT-PCR. (a) In situ hybridization
HOXB9 in resected colorectalcancer specimens (As, AntiSense). (b) HOXB9
expression of resected specimens and recurrence. (c) mRNA expression of
HOXB9 in human colorectal cancer cell lines were evaluated in triplicate in
qRT-PCR (d) mRNA expression of HOXB9 determined by RT-PCR. (e) Western
blotting of HOXB9 and related proteins. p values by the U test.
Additional file 2: Figure S2. (a, b) Impact of HOXB9 expression on
cytokine and cell proliferation in vitro. Cytokine secretion in HOXB9-over
expressing cell lines (n=8). CXCR8 (a) and VEGF (b). (c) Immunohisto-
chemical staining of paraffin-embeddedxenografts obtain from HT29-T
cancer cells. Samples were stained in anti-HOXB9 or anti-CD34 antibody.
(d) Immunohistostaining of xenografts using anti IL8 antibody and anti
VEGF antibody. Error bars are SDs. * p <0.05 by U-test.
Additional file 3: Figure S3. (a and b) In vitro cell proliferation of
HOXB9 regulated cells evaluated in Edu assays (a) and MU assays (b).
(a) Cell proliferation for 24 hours after the induction of HOXB9 in HT29-T
cells and HCT116-T cells were evaluated in flow cytometry. (b) Cell
proliferation and survival for 7 days in four HOXB9 regulated cell lines
were examined in MU assays (n=8 each). (c and d) Schematic illustration
of coculture systems of tumor cells and HUVECs co-culture systems.
Tumors were co-cultured with HUVECs and human fibroblast in the same
medium via micro-pore membrane with or without tetracycline to
regulate HOXB9 expression to mimic the microenvironment (c). Tumors
communicated with microenvironmental cells in a paracrine way (d).
(e and f) Immunocytochemical stainings of HUVECs in co-culture system
with or without bevacizumab. HUVECs co-cultured with HT29-T (e) or
WiDr-S (f) were stained using anti CD31 antibody. Error bars are SDs.
Additional file 4: Figure S4. Bevacizumab treatment and HOXB9
expression (a-d) Tumor growth under bevacizumab treatment in HCT
116-T xenograft models in Balb/c flu/flu mice (n = 8 each). (a) Tumor
burden were calculated every 3-4 days. (b) Tumor weight were measured at
the time of sacrifice. (c) The size of specimens were also evaluated at the
time of sacrifice. (d) Tumor inhibition rate was calculated in Ha 116- T on
day 21. Error bars are SDs. *p < 0.05 and tp < 0.005 by U-test.
Additional file 5: Figure S5. Xenografted animals treated with
bevacizumab and sunitinib. (a and b) HOXB9 expression and
bevacizumab treatment were evaluated in ISP model of HCT116-T cells
in Balb/c mice (n = 8). Kaplan-Meier curves for each group (a) and
third-quadrant survival period for bevacizumab treatment (b) were
analyzed in these mice. (c) Tumor growth under sunitinib treatment in
an MCF 1OA-RAS xenograft model in Balb/c nu/nu mice (n = 8). Error
bars are SDs. tp < 0.005 by U-test.
Additional file 6: Figure S6. HOXB9 expression and co-culture systems
in WiDr cells. (a) Cytokines in supernatants of co-cultured cell lines,
detected by ELISA (no significant difference, n8 each). (b) Tumor proliferation
of WiDr shHOXB9 and scramble cell lines on treatment with bevacizumab
andlor an 1L6-neutralizing antibody in the co-culture system. (c) Scheme of
the hypothesis in the present study. Error bars are SDs. p values by U-test.
Additional file 7: Table S1. Consecutive colorectal cancer patients who
received bevacizumab treatment after tumor resection were enrolled in
this study.
Additional file 8: Table S2. Primer sequence in this study.
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